Nevro Corp. (NVRO)

Market Cap	221.21M
Revenue (ttm)	408.52M -3.9%
Net Income	-113.44M
EPS	-3.06
Shares Out	37.88M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	751,504
Open	5.84
Previous Close	5.84
Day's Range	5.84 - 5.86
52-Week Range	3.17 - 13.84
Beta	0.82
Analysts	Hold
Price Target	7.24 (+23.97%)
Earnings Date	May 6, 2025

About NVRO

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS systems. It also offers Senza HFX iQ platform that includes HFX iQ implantable pulse generator, HFX trial stimula...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 6, 2014
• Employees: 1,099
• Stock Exchange: NYSE
• Ticker Symbol: NVRO
• Website: https://nevro.com

Financial Performance

In 2024, Nevro's revenue was $408.52 million, a decrease of -3.92% compared to the previous year's $425.17 million. Losses were -$113.44 million, 23.0% more than in 2023.

Analyst Summary

According to 12 analysts, the average rating for NVRO stock is "Hold." The 12-month stock price target is $7.24, which is an increase of 23.97% from the latest price.

Price Target

$7.24

(23.97% upside)

Analyst Consensus: Hold